\

Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Press Releases

Get News Alerts by Email

Feb 27, 2020

Trovagene Announces Fourth Quarter and Full-Year 2019 Results
Feb 13, 2020

Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients

- Onvansertib demonstrates efficacy in Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC) across known androgen receptor resistance mechanisms
Feb 5, 2020

Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
Jan 29, 2020

Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
Jan 27, 2020

Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients

- All patients showed tumor regression by radiographic scan at 8 weeks and confirmation by further tumor shrinkage at 16 weeks; clinical benefit achieved in 100% (n=5) of patients

Show per page